Sunday, 19 November 2017
We expect big numbers to kick in from FY20-FY21: Kiran Mazumdar Shaw, Biocon
Talking to ET Now, Kiran Mazumdar Shaw, Biocon , says betting big on biosimilars and trastuzumab. Shaw says it is a huge opportunity for the company and she expects big numbers because there is going to be a ramp-up phase. An EIR is coming for one of your key facilities, this must be a big relief.
You can read more here: We expect big numbers to kick in from FY20-FY21: Kiran Mazumdar Shaw, Biocon
Subscribe to:
Post Comments (Atom)
Life insurers earn more in Oct selling lesser policies
The 24-company Indian life insurance industry closed last month with new business of Rs 22,776.03 crore, up by 31.87 per cent over the prev...
No comments:
Post a Comment